UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Avatar

ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss and Overcoming Resistance, Targeting CD19 and CD22 & BiTEs

By UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review FEATURING Nathan H. Fowler
By UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review FEATURING Nathan H. Fowler
1,069 views
March 9, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

Feat. R. Gale
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
08:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outpatient Management of CAR-T and Bi-Speci…

Feat. R. Bansal
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
09:45
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Therapeutic Options for Pts With Primary …

Feat. M. Kamdar
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
10:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Rates of CRS and ICANS From CIBMTR Data o…

Feat. J. DiPersio
25:44
Tara Graff

DLBCL Updates From iCML 2023

07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

35:28
UNC Lineberger Comprehensive Cancer Center

DLBCL Management: Updates for 2023

Feat. N. Grover